The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I, including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as active ingredient; uses in the preparation of vascular endothelial growth factor receptor tyrosine kinase inhibitors, and uses in the preparation of medicament for the treatment and/or prevention of cancer.
本发明属于药物领域。本发明涉及根据公式I的化合物,包括它们的光学活性形式、药物可接受的盐或
水合物,以及包含它们作为活性成分的药物组合物;用于制备血管内皮生长因子受体
酪氨酸激酶
抑制剂的使用,以及用于制备治疗和/或预防癌症的药物的使用。